Figure 4
Figure 4. Survival rates and pathologic findings in TCF8 mutant mice. (A) The survival rates of a cohort of wild-type (wild), TCF8 heterozygous (hetero), and TCF8 homozygous (homo) mutant mice were followed over the indicated period using Kaplan-Meier plots. (B) Gross photograph of TCF8 mutant mice with ascites (◀). Approximately 30% of TCF8-homologous mutant mice showed curled tail (). (C) Bloody or milky ascites was pooled. (D) May-Giemsa staining of tumor cells in ascites. Original magnification ×400. (E) Many lymphoma cells with medium- to large-sized nuclei infiltrated in the mesentery. Cells were examined using an Axioskop 2 plus inverted microscope (Carl Zeiss, Rugby, United Kingdom) and digital images were aquired using AxioCam camera and AxioVision 2.05 software (Carl Zeiss). Original magnification ×400. (F) Tumor cells from ascitic fluids were analyzed by staining with a combination of monoclonal antibodies, either Thy1.2-PE with B220-FITC (left) or CD4-PE with CD8-FITC (right) and FACS. (G,H) The tumor cells that invaded liver (G) or spleen (H) were analyzed by staining with a combination of monoclonal antibodies, CD4-PE with CD8-FITC.

Survival rates and pathologic findings in TCF8 mutant mice. (A) The survival rates of a cohort of wild-type (wild), TCF8 heterozygous (hetero), and TCF8 homozygous (homo) mutant mice were followed over the indicated period using Kaplan-Meier plots. (B) Gross photograph of TCF8 mutant mice with ascites (◀). Approximately 30% of TCF8-homologous mutant mice showed curled tail (). (C) Bloody or milky ascites was pooled. (D) May-Giemsa staining of tumor cells in ascites. Original magnification ×400. (E) Many lymphoma cells with medium- to large-sized nuclei infiltrated in the mesentery. Cells were examined using an Axioskop 2 plus inverted microscope (Carl Zeiss, Rugby, United Kingdom) and digital images were aquired using AxioCam camera and AxioVision 2.05 software (Carl Zeiss). Original magnification ×400. (F) Tumor cells from ascitic fluids were analyzed by staining with a combination of monoclonal antibodies, either Thy1.2-PE with B220-FITC (left) or CD4-PE with CD8-FITC (right) and FACS. (G,H) The tumor cells that invaded liver (G) or spleen (H) were analyzed by staining with a combination of monoclonal antibodies, CD4-PE with CD8-FITC.

Close Modal

or Create an Account

Close Modal
Close Modal